G

GRAIL, Inc. (GRAL)

NMS – Real vaqt narxi. Valyuta: USD

61.98

+0.72 (1.18%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

G

GRAIL, Inc. (GRAL)

NMS – Real vaqt narxi. Valyuta: USD

61.98

+0.72 (1.18%)

Yopilishda: May 12, 2026, 4:00 PM EDT

13.05.2026

GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

06.05.2026

Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking

Los Angeles, CA, May 06, 2026 (GLOBE NEWSWIRE) -- For 600 years, the cigar industry has remained stagnant, bound by a tradition that ignored the fundamental laws of thermodynamics. Today, El Septimo Geneva and its Chairman, billionaire engineer Zaya Younan, announce a breakthrough that transcends luxury: the Patented Refrigerated Ashtray.

06.05.2026

GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript

05.05.2026

GRAIL Reports First Quarter 2026 Financial Results

Q1 Galleri ® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000 Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platform to Expand Access Nationwide New Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting MENLO PARK, Calif., May 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026.

28.04.2026

Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

22.04.2026

GRAIL to Announce First Quarter 2026 Financial Results

MENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026.

21.04.2026

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation More than 174,000 Participants Enrolled Across Both Studies, Demonstrating the Scientific Rigor of Galleri ® Clinical Development Program MENLO PARK, Calif., April 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29-June 2, 2026.

Videolar

18.12.2025

Positive

Trump Media CEO: 'NUCLEAR FUSION is the HOLY GRAIL'

Press-relizlar

06.05.2026

Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking

Los Angeles, CA, May 06, 2026 (GLOBE NEWSWIRE) -- For 600 years, the cigar industry has remained stagnant, bound by a tradition that ignored the fundamental laws of thermodynamics. Today, El Septimo Geneva and its Chairman, billionaire engineer Zaya Younan, announce a breakthrough that transcends luxury: the Patented Refrigerated Ashtray.

05.05.2026

GRAIL Reports First Quarter 2026 Financial Results

Q1 Galleri ® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000 Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platform to Expand Access Nationwide New Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting MENLO PARK, Calif., May 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026.

15.04.2026

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, April 15, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights.

07.04.2026

GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide

Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient Portal Collaboration With Epic Will Allow Clinicians to Seamlessly Order the Galleri Multi-Cancer Early Detection Test at the Point of Care MENLO PARK, Calif., April 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Epic to bring the Galleri® multi-cancer early detection test into one of the nation's most widely used electronic health record (EHR) platforms, supporting broader adoption across health systems in the United States.

Search stocks

GRAIL, Inc. (GRAL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

GRAIL, Inc. (GRAL)

GRAIL, Inc. (GRAL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking

GRAIL, Inc. (GRAL) Q1 2026 Earnings Call Transcript

GRAIL Reports First Quarter 2026 Financial Results

Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know

GRAIL to Announce First Quarter 2026 Financial Results

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting

Videolar

Press-relizlar

Zaya Younan Unveils the Scientific Holy Grail of Cigar Smoking

GRAIL Reports First Quarter 2026 Financial Results

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES

GRAIL Announces Integration of the Galleri® Test into Epic Electronic Health Record Platform to Expand Access Nationwide